The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

As a cancer survivor, I face added stress with an upcoming black belt test and "scanxiety" before my annual CT scan and ...

IDEXX Laboratories exceeded fourth-quarter profit and revenue estimates on sales of its animal testing products and price increases.

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...

Doctors are enrolling patients in a groundbreaking clinical trial aimed at reducing cancer recurrence in patients with ...

Otsuka has dumped a clutch of clinical cancer candidates on Valentine's day. | Otsuka has broken up with a clutch of clinical ...

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

For media inquiries contact: Sudha Sruthi, Corporate Development email us here ...

Anivive, a software-driven pet health company, today announced the successful completion of its pivotal field study evaluating the safety and effectiveness of LAVERDIA®-CA1 (verdinexor tablets) in ...